<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35984816</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Coronavirus Disease 2019 Severity and Risk of Subsequent Cardiovascular Events.</ArticleTitle><Pagination><StartPage>e42</StartPage><EndPage>e50</EndPage><MedlinePgn>e42-e50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciac661</ELocationID><Abstract><AbstractText Label="BACKGROUND">Little is known about the relationship between coronavirus disease 2019 (COVID-19) severity and subsequent risk of experiencing a cardiovascular event (CVE) after COVID-19 recovery. We evaluated this relationship in a large cohort of United States adults.</AbstractText><AbstractText Label="METHODS">Using a claims database, we performed a retrospective cohort study of adults diagnosed with COVID-19 between 1 April 2020 and 31 May 2021. We evaluated the association between COVID-19 severity and risk of CVE &gt;30 days after COVID-19 diagnosis using inverse probability of treatment-weighted competing risks regression. Severity was based on level of care required for COVID-19 treatment: intensive care unit (ICU) admission, non-ICU hospitalization, or outpatient care only.</AbstractText><AbstractText Label="RESULTS">A total of 1 357 518 COVID-19 patients were included (2% ICU, 3% non-ICU hospitalization, and 95% outpatient only). Compared to outpatients, there was an increased risk of any CVE for patients requiring ICU admission (adjusted hazard ratio [aHR], 1.80 [95% confidence interval {CI}, 1.71-1.89]) or non-ICU hospitalization (aHR, 1.28 [95% CI, 1.24-1.33]). Risk of subsequent hospitalization for CVE was even higher (aHRs, 3.47 [95% CI, 3.20-3.76] for ICU and 1.96 [95% CI, 1.85-2.09] for non-ICU hospitalized vs outpatient only).</AbstractText><AbstractText Label="CONCLUSIONS">COVID-19 patients hospitalized or requiring critical care had a significantly higher risk of experiencing and being hospitalized for post-COVID-19 CVE than patients with milder COVID-19 who were managed solely in the outpatient setting, even after adjusting for differences between these groups. These findings underscore the continued importance of preventing severe acute respiratory syndrome coronavirus 2 infection from progressing to severe illness to reduce potential long-term cardiovascular complications.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wiemken</LastName><ForeName>Timothy L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>Leah J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Kathleen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Farid</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhotra</LastName><ForeName>Deepa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfred</LastName><ForeName>Tamuno</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puzniak</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thoburn</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jodar</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006331" MajorTopicYN="Y">Heart Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID syndrome</Keyword><Keyword MajorTopicYN="N">postacute COVID-19 syndrome</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. All authors are employees and shareholders of Pfizer Inc. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>19</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35984816</ArticleId><ArticleId IdType="pmc">PMC9907540</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac661</ArticleId><ArticleId IdType="pii">6671924</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, et al. . Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun 2022; 13:1957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. . Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 2021; 4:e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang F, Shen Y, et al. . Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. JAMA Netw Open 2021; 4:e2127403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482055</ArticleId><ArticleId IdType="pubmed">34586367</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397:220&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Yomogida K, Zhu S, Rubino F, Figueroa W, Balanji N, Holman E. Post-acute sequelae of SARS-CoV-2 infection among adults aged &#x2265;18 years&#x2014;Long Beach, California, April 1&#x2013;December 10, 2020. MMWR Morb Mortal Wkly Rep 2021; 70:1274&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8445372</ArticleId><ArticleId IdType="pubmed">34529639</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med 2021; 27:601&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein LR, Rose EB, Horwitz SM, et al. . Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020; 383:334&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7346765</ArticleId><ArticleId IdType="pubmed">32598831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell ML, Catalfamo CJ, Farland LV, et al. . Post-acute sequelae of COVID-19 in a non-hospitalized cohort: results from the Arizona CoVHORT. PLoS One 2021; 16:e0254347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8336814</ArticleId><ArticleId IdType="pubmed">34347785</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett CE, Koyama AK, Alvarez P, et al. . Risk for newly diagnosed diabetes &gt;30 days after SARS-CoV-2 infection among persons aged &lt;18 years&#x2014;United States, March 1, 2020&#x2013;June 28, 2021. MMWR Morb Mortal Wkly Rep 2022; 71:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757617</ArticleId><ArticleId IdType="pubmed">35025851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 2020; 77:1018&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484225</ArticleId><ArticleId IdType="pubmed">32469387</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021; 594:259&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022; 28:583&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan BE, Cheung C. Post COVID-19 arterial thromboembolism: a clear and present danger. Semin Thromb Hemost 2022; 48:112&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">33860515</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kindi S, Zidar DA. COVID-lateral damage: cardiovascular manifestations of SARS-CoV-2 infection. Transl Res 2022; 241:25&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8588575</ArticleId><ArticleId IdType="pubmed">34780967</ArticleId></ArticleIdList></Reference><Reference><Citation>Szekely Y, Lichter Y, Sadon S, et al. . Cardiorespiratory abnormalities in patients recovering from coronavirus disease 2019. J Am Soc Echocardiogr 2021; 34:1273&#x2013;84.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8425293</ArticleId><ArticleId IdType="pubmed">34508837</ArticleId></ArticleIdList></Reference><Reference><Citation>Szarpak L, Pruc M, Filipiak KJ, et al. . Myocarditis: a complication of COVID-19 and long-COVID-19 syndrome as a serious threat in modern cardiology. Cardiol J 2021; 29:178&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8890406</ArticleId><ArticleId IdType="pubmed">34811716</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xe5;hlberg M, Reistam U, Fedorowski A, et al. . Post-COVID-19 tachycardia syndrome: a distinct phenotype of post-acute COVID-19 syndrome. Am J Med 2021; 134:1451&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8356730</ArticleId><ArticleId IdType="pubmed">34390682</ArticleId></ArticleIdList></Reference><Reference><Citation>Soeiro AM, P&#xea;go-Fernandes PM. Post-COVID-19 cardiological alterations. Sao Paulo Med J 2021; 139:543&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9634840</ArticleId><ArticleId IdType="pubmed">34468629</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammad M, Emin M, Bhutta A, Gul EH, Voorhees E, Afzal MR. Cardiac arrhythmias associated with COVID-19 infection: state of the art review. Expert Rev Cardiovasc Ther 2021; 19:881&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8607535</ArticleId><ArticleId IdType="pubmed">34702128</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakatos BK, Tokodi M, F&#xe1;bi&#xe1;n A, et al. . Frequent constriction-like echocardiographic findings in elite athletes following mild COVID-19: a propensity score&#x2013;matched analysis. Front Cardiovasc Med 2022; 8:760651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767617</ArticleId><ArticleId IdType="pubmed">35071343</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoularis I, Fonseca-Rodr&#xed;guez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet 2021; 398:599&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8321431</ArticleId><ArticleId IdType="pubmed">34332652</ArticleId></ArticleIdList></Reference><Reference><Citation>Farshidfar F, Koleini N, Ardehali H. Cardiovascular complications of COVID-19. JCI Insight 2021; 6:e148980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410051</ArticleId><ArticleId IdType="pubmed">34061779</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung MK, Zidar DA, Bristow MR, et al. . COVID-19 and cardiovascular disease: from bench to bedside. Circ Res 2021; 128:1214&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8048382</ArticleId><ArticleId IdType="pubmed">33856918</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandopadhyay A, Singh AK, Chaubey G. COVID-19: the cause of the manifested cardiovascular complications during the pandemic. Front Cardiovasc Med 2021; 8:744482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8581218</ArticleId><ArticleId IdType="pubmed">34778405</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocoros NM, Fuller CC, Adimadhyam S, et al. . A COVID-19-ready public health surveillance system: the Food and Drug Administration&#x2019;s sentinel system. Pharmacoepidemiol Drug Saf 2021; 30:827&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8250843</ArticleId><ArticleId IdType="pubmed">33797815</ArticleId></ArticleIdList></Reference><Reference><Citation>
US Food and Drug Administration Sentinel Initiative . COVID-19 natural history codelist. Available at: https://www.sentinelinitiative.org/sites/default/files/Methods/COVID-19_Natural-History-Codelist.xlsx. Accessed 29 June 2022.</Citation></Reference><Reference><Citation>Di Fusco M, Vaghela S, Moran MM, et al. . COVID-19-associated hospitalizations among children less than 12 years of age in the United States. J Med Econ 2022; 25:334&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">35293285</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen KM, Mehta HB, Palamuttam N, et al. . Association between chronic use of immunosuppressive drugs and clinical outcomes from coronavirus disease 2019 (COVID-19) hospitalization: a retrospective cohort study in a large US health system. Clin Infect Dis 2021; 73:e4124&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953980</ArticleId><ArticleId IdType="pubmed">33410884</ArticleId></ArticleIdList></Reference><Reference><Citation>
von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Available at: https://www.equator-network.org/reporting-guidelines/strobe/. Accessed 2 March 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke KEN, Jones JM, Deng Y, et al. . Seroprevalence of infection-induced SARS-CoV-2 antibodies&#x2014;United States, September 2021&#x2013;February 2022. MMWR Morb Mortal Wkly Rep 2022; 71:606&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9098232</ArticleId><ArticleId IdType="pubmed">35482574</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhi SA, Kwatra G, Myers JE, et al. . Population immunity and Covid-19 severity with Omicron variant in South Africa. N Engl J Med 2022; 386:1314&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908853</ArticleId><ArticleId IdType="pubmed">35196424</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovanoski N, Chen X, Becker U, et al. . Severity of COVID-19 and adverse long-term outcomes: a retrospective cohort study based on a US electronic health record database. BMJ Open 2021; 11:e056284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9065767</ArticleId><ArticleId IdType="pubmed">34893488</ArticleId></ArticleIdList></Reference><Reference><Citation>Block JP, Boehmer TK, Forrest CB, et al. . Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination&#x2014;pCORnet, United States, January 2021&#x2013;January 2022. MMWR Morb Mortal Wkly Rep 2022; 71:517&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989373</ArticleId><ArticleId IdType="pubmed">35389977</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351:2611&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15602021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez J, Aliberti S, Mirsaeidi M, et al. . Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008; 47:182&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18533841</ArticleId></ArticleIdList></Reference><Reference><Citation>Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007; 45:158&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">17578773</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998; 351:1467&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">9605802</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkind MS, Carty CL, O'Meara ES, et al. . Hospitalization for infection and risk of acute ischemic stroke: the Cardiovascular Health Study. Stroke 2011; 42:1851&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125478</ArticleId><ArticleId IdType="pubmed">21546476</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalager-Pedersen M, Sogaard M, Schonheyder HC, Nielsen H, Thomsen RW. Risk for myocardial infarction and stroke after community-acquired bacteremia: a 20-year population-based cohort study. Circulation 2014; 129:1387&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">24523433</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrales-Medina VF, Serpa J, Rueda AM, et al. . Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore) 2009; 88:154&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19440118</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrales-Medina VF, Fatemi O, Serpa J, et al. . The association between Staphylococcus aureus bacteremia and acute myocardial infarction. Scand J Infect Dis 2009; 41(6&#x2013;7):511&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19396667</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliberti S, Ramirez JA. Cardiac diseases complicating community-acquired pneumonia. Curr Opin Infect Dis 2014; 27:295&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">24685550</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang TY, Chao TF, Liu CJ, et al. . The association between influenza infection, vaccination, and atrial fibrillation: a nationwide case-control study. Heart Rhythm 2016; 13:1189&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">26850784</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou SM, Chu H, Chao PW, et al. . Long-term mortality and major adverse cardiovascular events in sepsis survivors. A nationwide population-based study. Am J Respir Crit Care Med 2016; 194:209&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">26808711</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. . Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015; 313:264&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687729</ArticleId><ArticleId IdType="pubmed">25602997</ArticleId></ArticleIdList></Reference><Reference><Citation>Yende S, Linde-Zwirble W, Mayr F, Weissfeld LA, Reis S, Angus DC. Risk of cardiovascular events in survivors of severe sepsis. Am J Respir Crit Care Med 2014; 189:1065&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098105</ArticleId><ArticleId IdType="pubmed">24456535</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B, Bluemke DA, Luscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J 2022; 43:1157&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903393</ArticleId><ArticleId IdType="pubmed">35176758</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, et al. . New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun 2021; 12:5417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022; 185:881&#x2013;95.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Blagova O, Varionchik N, Zaidenov V, Savina P, Sarkisova N. Anti-heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID-19. Eur J Immunol 2021; 51:893&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">33368288</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>